(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback